Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Regents of the University of California has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. Prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. This specific snapshot shows a very limited volume of active patent office correspondence for the entity relative to its potential size. The focus on 1 distinct art unit indicates that the current pending matter falls within a specific technical domain.
YU, DAVID TUYANG serves as the busiest examiner for the portfolio with 1 pending office action. This single action represents the total pending workload for the university's current filings in this data set. With only 1 distinct examiner involved, the university's immediate success in this technology area is contingent upon the findings of a single individual. The absence of multiple pending office actions suggests that other filings may be in different stages of the patent lifecycle. For practitioners, this means that the current prosecution strategy is highly centralized and lacks the complexity of larger, more distributed portfolios.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18254086 | CRISPR RIBONUCLEOPROTEIN COMPLEX GENOME EDITING OF HUMAN INNATE IMMUNE CELLS | YU, DAVID TUYANG | 71d |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18254086 | CRISPR RIBONUCLEOPROTEIN COMPLEX GENOME EDITING OF HUMAN INNATE IMMUNE CELLS | YU, DAVID TUYANG | 1635 | §102§103§112DPOther | Non-Final OA | 71d | Pending | May 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial